CurrentEndo coverage · page 54 of 55

Diabetes, Obesity and Metabolism

Briefs 2,121–2,160 of 2,200 CurrentEndo has covered from this journal, newest publication first

Latest from Diabetes, Obesity and Metabolism

All coverage, newest first

Diabetes Obes Metab6 Jan 2023
Hepatic steatosis and advanced hepatic fibrosis are independent predictors of long‐term mortality in acute myocardial infarction
Cohort studyLipids & liver
Diabetes Obes Metab3 Jan 2023
Changes in the use of glucose‐lowering drugs: A Danish nationwide study
Cohort studyT2D & other
Diabetes Obes Metab3 Jan 2023
Impact of a multicomponent healthcare intervention on glycaemic control in subjects with poorly controlled type 2 diabetes: The INTEGRA study
Randomized controlled trialT2D & other
Diabetes Obes Metab3 Jan 2023
Metabolic and physiological responses to graded exercise testing in individuals with type 1 diabetes using insulin pump therapy
Meta-analysisT1D
Diabetes Obes Metab3 Jan 2023
Reduction of cardiac adipose tissue volume with short‐term empagliflozin treatment in patients with type 2 diabetes: A substudy from the SIMPLE randomized clinical trial
Secondary analysisT2D & other
Diabetes Obes Metab3 Jan 2023
Semaglutide delays 4‐hour gastric emptying in women with polycystic ovary syndrome and obesity
Randomized controlled trialReproductive endocrine
Diabetes Obes Metab27 Dec 2022
Achievement of glycaemic targets with weight loss and without hypoglycaemia in type 2 diabetes with the once‐weekly glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 receptor agonist tirzepatide: A post hoc analysis of the SURPASS ‐1 to ‐5 studies
Secondary analysisT2D & other
Diabetes Obes Metab27 Dec 2022
Age‐dependent prevalence of type 2 diabetes, cardiovascular risk profiles and use of diabetes drugs in Germany using health claims data
Cross-sectional studyT2D & other
Diabetes Obes Metab27 Dec 2022
Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis
Research articleT2D & other
Diabetes Obes Metab26 Dec 2022
Cardiorenal outcomes by indices of liver steatosis and fibrosis in individuals with type 2 diabetes and atherosclerotic cardiovascular disease: Analyses from VERTIS CV , a randomized trial of the sodium‐glucose cotransporter‐2 inhibitor ertugliflozin
Secondary analysisT2D & other
Diabetes Obes Metab22 Dec 2022
Safety, tolerability, pharmacodynamics and pharmacokinetics following once‐daily doses of BI 187004, an inhibitor of 11 beta‐hydroxysteroid dehydrogenase‐1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity
Randomized controlled trialT2D & other
Diabetes Obes Metab20 Dec 2022
Effectiveness and safety of early insulin glargine administration in combination with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: A randomized controlled trial
Randomized controlled trialT1D
Diabetes Obes Metab20 Dec 2022
Objective sleep characteristics and continuous glucose monitoring profiles of type 2 diabetes patients in real‐life settings
Cohort studyT2D & other
Diabetes Obes Metab20 Dec 2022
Validation of a risk prediction model for early chronic kidney disease in patients with type 2 diabetes: Data from the German/Austrian Diabetes Prospective Follow‐up registry
Diagnostic or prognostic studyT2D & other
Diabetes Obes Metab19 Dec 2022
A phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of danuglipron ( PF ‐06882961), an oral small‐molecule glucagon‐like peptide‐1 receptor agonist, in Japanese adults with type 2 diabetes mellitus
Randomized controlled trialT2D & other
Diabetes Obes Metab12 Dec 2022
Efficacy and safety of janagliflozin as add‐on therapy to metformin in Chinese patients with type 2 diabetes inadequately controlled with metformin alone: A multicentre, randomized, double‐blind, placebo‐controlled, phase 3 trial
Randomized controlled trialT2D & other
Diabetes Obes Metab9 Dec 2022
Effects of intensive blood pressure lowering in patients with diabetes: A pooled analysis of the STEP and ACCORD‐BP randomized trials
Meta-analysisT2D & other
Diabetes Obes Metab9 Dec 2022
Safety and efficacy of an oral insulin ( Capsulin ) in patients with early‐stage type 2 diabetes: A dose‐ranging phase 2b study
Randomized controlled trialT2D & other
Diabetes Obes Metab7 Dec 2022
Medical and surgical treatment of postbariatric hypoglycaemia: Retrospective data from daily practice
Cohort studyObesity
Diabetes Obes Metab2 Dec 2022
Challenging the 50‐50 rule for the basal‐bolus insulin ratio in patients with type 2 diabetes who maintain stable glycaemic control
Cohort studyT2D & other
Diabetes Obes Metab2 Dec 2022
Model‐based predictions on health benefits and budget impact of implementing empagliflozin in people with type 2 diabetes and established cardiovascular disease
Cohort studyT2D & other
Diabetes Obes Metab2 Dec 2022
Nomogram model and risk score to predict 5‐year risk of progression from prediabetes to diabetes in Chinese adults: Development and validation of a novel model
Cohort studyT2D & other
Diabetes Obes Metab1 Dec 2022
Continuous glucose monitoring metrics (Mean Glucose, time above range and time in range) are superior to glycated haemoglobin for assessment of therapeutic efficacy
Secondary analysisTechnology
Diabetes Obes Metab29 Nov 2022
Chronic kidney disease begets heart failure and vice versa: temporal associations between heart failure events in relation to incident chronic kidney disease in type 2 diabetes
Cohort studyT2D & other
Diabetes Obes Metab28 Nov 2022
Burden of established cardiovascular disease in people with type 2 diabetes and matched controls: Hospital‐based care, days absent from work, costs and mortality
Cohort studyT2D & other
Diabetes Obes Metab25 Nov 2022
Comparison of two titration programmes for adding insulin detemir to oral antidiabetic drugs in patients with poorly controlled type 2 diabetes mellitus
Randomized controlled trialT2D & other
Diabetes Obes Metab24 Nov 2022
Liver fat is superior to visceral and pancreatic fat as a risk biomarker of impaired glucose regulation in overweight/obese subjects
Cross-sectional studyT2D & other
Diabetes Obes Metab23 Nov 2022
Findings for iGlarLixi versus BIAsp 30 confirmed in groups of people with type 2 diabetes with different biomedical characteristics
Secondary analysisT2D & other
Diabetes Obes Metab21 Nov 2022
A multicentre, randomized, double‐blind, parallel, active‐ and placebo‐controlled Phase 3 clinical study of the glucokinase activator PB ‐201 in treatment‐naive patients with type 2 diabetes mellitus: A study protocol
Trial designT2D & other
Diabetes Obes Metab21 Nov 2022
Oral insulin ( ORMD ‐0801) in type 2 diabetes mellitus: A dose‐finding 12‐week randomized placebo‐controlled study
Randomized controlled trialT2D & other
Diabetes Obes Metab21 Nov 2022
Safety and efficacy of liraglutide on reducing visceral and ectopic fat in adults with or without type 2 diabetes mellitus: A systematic review and meta‐analysis
Meta-analysisT2D & other
Diabetes Obes Metab21 Nov 2022
Weight management in young adults with type 1 diabetes: The advancing care for type 1 diabetes and obesity network sequential multiple assignment randomized trial pilot results
Randomized controlled trialObesity
Diabetes Obes Metab15 Nov 2022
Associations of liver fat content with cardiometabolic phenotypes and outcomes in a multi‐ethnic population: Results from the Dallas Heart Study
Cohort studyLipids & liver
Diabetes Obes Metab14 Nov 2022
C ontinuous glucose monitoring‐based time‐in‐range using insulin glargine 300 units/ ml versus insulin degludec 100 units/ ml in type 1 diabetes: The head‐to‐head randomized controlled InRange trial
Randomized controlled trialT1D
Diabetes Obes Metab10 Nov 2022
Comparative effects of weight loss and incretin‐based therapies on vascular endothelial function, fibrinolysis and inflammation in individuals with obesity and prediabetes: A randomized controlled trial
Randomized controlled trialT2D & other
Diabetes Obes Metab7 Nov 2022
Eight‐year trends in obesity‐related complications and health care cost progression in a US population with obesity: A retrospective cohort study
Cohort studyObesity
Diabetes Obes Metab4 Nov 2022
Pioglitazone reduces epicardial fat and improves diastolic function in patients with type 2 diabetes
Cohort studyT2D & other
Diabetes Obes Metab2 Nov 2022
Age‐specific associations between the number of co‐morbidities, all‐cause mortality and public direct medical costs in patients with type 2 diabetes: A retrospective cohort study
Cohort studyT2D & other
Diabetes Obes Metab2 Nov 2022
Change in pharmacodynamic variables following once‐weekly tirzepatide treatment versus dulaglutide in Japanese patients with type 2 diabetes ( SURPASS J‐mono substudy)
Secondary analysisT2D & other
Diabetes Obes Metab2 Nov 2022
Changes in racial and ethnic disparities in glucose‐lowering drug utilization and glycated haemoglobin A1c in US adults with diabetes: 2005‐2018
Cross-sectional studyT2D & other

All 2,200 Briefs in ExploreShowing Briefs 2,121–2,160 of 2,200, newest first